Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II a double-blind, randomized, placebo-controlled, dose-finding study to evaluate the safety, dose, route of administration, immunogenicity and affect of ISR's spike-based inhalation / nasal vaccine formulations in healthy subjects

Next Previous
X
Search
Trial Profile

A phase I/II a double-blind, randomized, placebo-controlled, dose-finding study to evaluate the safety, dose, route of administration, immunogenicity and affect of ISR's spike-based inhalation / nasal vaccine formulations in healthy subjects

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ISR 52 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 01 Jul 2022 According to an ISR media release, company has received approval from BMRC NREC for this trial in Bangladesh.
    • 02 Jun 2022 According to Immune System Regulation media release, the company has conducted an audit of the clinical trial center, the clinical laboratory and our CRO, which will be responsible for the operational operation and implementation of the clinical study.
    • 21 Feb 2022 According to Immune System Regulation media release, the company has submitted an application to the Bangladesh Medical Research Council (BMRC) to lead the approval process for conducting a Phase I / II study with ISR52 nasal dry powder vaccine against SARS CoV-2.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top